Inhaled corticosteroids reduce asthma-associated airway hyperperfusion through genomic and nongenomic mechanisms

Gabor Horvath, Szilvia Vasas, Adam Wanner

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

Inhaled corticosteroids have both genomic and nongenomic actions on the tracheobronchial (airway) vasculature in patients with bronchial asthma. Genomic actions involve the activation or repression of target genes associated with inflammation, and reduce inflammatory hyperperfusion in the airway. In contrast, nongenomic actions are mediated by rapid cellular mechanisms, and induce transient vasoconstriction. This article reviews recent progress on the mechanisms by which inhaled corticosteroids reverse inflammatory blood flow changes in the airway in asthma.

Original languageEnglish (US)
Pages (from-to)157-162
Number of pages6
JournalPulmonary Pharmacology and Therapeutics
Volume20
Issue number2
DOIs
StatePublished - Apr 2007

Keywords

  • Airway blood flow
  • Asthma
  • Bronchial circulation
  • Inhaled corticosteroids
  • Nongenomic action
  • Vasoconstriction

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology

Fingerprint Dive into the research topics of 'Inhaled corticosteroids reduce asthma-associated airway hyperperfusion through genomic and nongenomic mechanisms'. Together they form a unique fingerprint.

Cite this